• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Management of SARS-CoV-2 Pneumonia

tetano

Editor, Senior Moderator
J Med Virol


. 2020 Aug 28.
doi: 10.1002/jmv.26470. Online ahead of print.
Management of SARS-CoV-2 Pneumonia


Caterina Sagnelli[SUP] 1 [/SUP], Benito Celia[SUP] 2 [/SUP], Caterina Monari[SUP] 1 [/SUP], Salvatore Cirillo[SUP] 2 [/SUP], Giulia De Angelis[SUP] 1 [/SUP], Andrea Bianco[SUP] 2 [/SUP], Nicola Coppola[SUP] 1 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world since December 2019 to become a global public health emergency for the elevated deaths and hospitalizations in Intensive Care Units. The severity spectrum of SARS-CoV-2 pneumonia ranges from mild to severe clinical conditions. The clinical course of SARS-CoV-2 disease is correlated with multiple factors including host characteristics (genetics, immune status, age and general health), viral load and, above all, the host distribution of the airways and lungs of the viral receptor cells. In this review, we will briefly summarize the current knowledge on the characteristics and management of COVID-19-pneumonia. However, other studies are needed to better understand the pathogenetic mechanisms induced by SARS-Cov-2 infection, and to evaluate the long-term consequences of the virus on the lungs. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; clinical presentation; pneumonia.
 
Back
Top Bottom